BioCryst Pharmaceuticals Inc BCRX
News
BioCryst Reports Third Quarter 2026 Financial Results
BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
BioCryst to Report Third Quarter 2026 Financial Results on November 4
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
BioCryst to Present at Upcoming Investor Conference
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
BioCryst Gets FDA OK for Pediatric Use of Orladeyo

